Clinical trial
ATROVENT HFA Actuation Indicator Open-Label Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)
NCT00928746 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- ATROVENT HFA Actuation Indicator Open-Label Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 30, 2009
- Completion date
- Not reported
- Enrollment
- 142 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.